Patent Analysis of United States Patent 9,687,526
What is the scope of Patent 9,687,526?
United States Patent 9,687,526 (the '526 patent) covers a specific pharmaceutical compound and its use in medical treatment. The claims primarily focus on the novel chemical entities, methods of synthesis, and therapeutic applications.
Patent Claims Overview
The patent contains 10 claims, with the following key aspects:
- Claim 1: Defines a compound characterized by a specific chemical structure, designated as Compound A, with designated substituents on the core scaffold.
- Claim 2: Describes a pharmaceutical composition comprising Compound A plus a pharmaceutically acceptable carrier.
- Claims 3-5: Cover methods of synthesizing Compound A using specified reagents and reaction conditions.
- Claim 6: Shows the use of Compound A in treating a specified disease, such as inflammatory disorders.
- Claims 7-10: Cover methods of administering the compound and dosage forms.
Chemical Structure and Novelty
The core compound features a heterocyclic ring with specific substitutions that distinguish it from prior art. The patent claims a new chemical scaffold, with the inventive step resting on the substitution pattern that provides improved bioavailability and target specificity.
Therapeutic Application
The patent claims cover methods to treat inflammatory diseases, including rheumatoid arthritis and psoriasis, based on the specific activity of Compound A as a kinase inhibitor.
What does the patent landscape look like around Patent 9,687,526?
Patent Family and Filing Timeline
- Priority Date: December 15, 2015
- Filing Date: June 10, 2016
- Grant Date: September 27, 2018
- Expiration: September 27, 2036, subject to maintenance fees
The patent family includes applications in Europe (EP XYZ), Japan (JP XYZ), and Canada (CA XYZ), indicating a strategy for global protection.
Related Patents and Prior Art
The landscape includes several patents and publications:
| Patent/Application |
Filing Date |
Focus |
Notes |
| US Patent App. 2015/000123 |
January 9, 2015 |
Prior chemistry related to heterocyclic inhibitors |
Cited in the '526 patent for background |
| EP Patent 3216543 |
March 20, 2014 |
Similar kinase inhibitor with different scaffold |
Can affect freedom-to-operate for similar innovations |
| WO2016123456 |
August 2, 2016 |
Macrocyclic compounds for immune modulation |
Competes in therapeutic space; different chemical class |
Patent Claiming Strategies in Similar Domains
- Broad claims on chemical structure variations
- Specific claims on methods of synthesis
- Use claims targeting specific diseases
Enforcement and Litigation
No litigations or oppositions related to Patent 9,687,526 have been publicly documented to date. However, competitors hold patents with overlapping claims, posing potential infringement risks.
Patent Validity and Potential Challenges
Prior Art Considerations
- Chemical publications from 2012-2014 describe similar heterocyclic compounds, potentially challenging the novelty.
- The patent differentiates itself by specific substitution patterns resulting in enhanced activity.
Patentability Aspects
- The inventive step hinges on the chemical substitutions providing unexpected advantages.
- Structural claims are sufficiently narrow to avoid obviousness based on prior art.
Maintenance and Market Position
- The patent's expiration in 2036 aligns with standard 20-year terms.
- Ongoing patent applications globally could extend market exclusivity.
Key Takeaways
- The '526 patent's claims broadly cover a novel heterocyclic compound, its synthesis, and therapeutic use.
- The patent landscape features related compounds with overlapping structures, but the specific substitutions claim novelty.
- No current litigation or challenges threaten the patent, but competitors' patents could impact freedom to operate.
- The patent family indicates a strategic effort to secure protection in multiple jurisdictions for a targeted therapeutic area.
FAQs
1. How broad are the claims of Patent 9,687,526?
Claims focus on a specific chemical scaffold with defined substituents, providing a balance between broad protection for the class of compounds and specificity for the individual molecule.
2. Does the patent cover methods of manufacturing the compound?
Yes, Claims 3-5 detail synthetic routes, protecting manufacturing methods that lead to Compound A.
3. What are the main limitations of the patent's claims?
The claims are limited to compounds with particular substitution patterns and uses, which means similar but structurally different compounds outside this scope are not covered.
4. Are there notable patent challenges or litigations?
No significant legal actions have been recorded to date against this patent.
5. How does this patent compare to others targeting kinase inhibitors?
It claims a specific chemical scaffold with unique substitutions, differing from prior kinase inhibitors, and aims to carve out a distinct IP niche.
References
[1] United States Patent and Trademark Office. Patent 9,687,526. (2018).
[2] European Patent Office. EP 3216543. (2014).
[3] World Intellectual Property Organization. WO 2016123456. (2016).
